NASDAQ: CNSPCns Pharmaceuticals Inc Stock
$4.29+0.01 (+0.23%)
Updated Jun 23, 2026
CNSP Price
$4.29
Fair Value Price
N/A
Market Cap
$6.27M
52 Week Low
$1.90
52 Week High
$12.36
P/E
-0.14x
P/B
88.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
64.81
Operating Cash Flow
-$15M
Beta
0.52
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNSP Overview
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNSP's potential to beat the market
- CNSP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CNSP
RankedUnranked of 467
RankedUnranked of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.25 | A | |
| $51.34 | A | |
| $2.17 | A |
Be the first to know about important CNSP news, forecast changes, insider trades & much more!
CNSP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNSP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNSP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CNSP is poor value based on its book value relative to its share price (88.67x), compared to the US Biotechnology industry average (5.15x)
P/B vs Industry Valuation
CNSP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CNSP due diligence checks available for Premium users.
Valuation
CNSP fair value
Fair Value of CNSP stock based on Discounted Cash Flow (DCF)
Price
$4.29
Fair Value
$15.50
Undervalued by
72.32%
CNSP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNSP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
15.59x
Market
7.68x
CNSP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
88.67x
Industry
5.15x
CNSP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNSP's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.9M
Profit Margin
0%
CNSP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.7M
Liabilities
$4.6M
Debt to equity
64.81
CNSP's short-term liabilities ($4.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNSP's short-term assets ($4.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNSP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CNSP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
-$6.2k
Financing
$404.7k
CNSP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNSP vs Biotech Stocks
Cns Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.